Joint research study by Hamad Medical Corporation and Weill Cornell Medicine-Qatar looks into the feasibility of saliva testing for diabetes
Early diagnosis and treatment is extremely important for patients with diabetes as it can significantly reduce the risk of developing complications.
Scientists from Hamad Medical Corporation (HMC) and Weill Cornell Medicine-Qatar (WCM-Q) have previously identified a biomarker (metabolite 1,5-anhydroglucitol – 1,5AG) that would allow for a noninvasive screening and monitoring of the disease from saliva. Using saliva rather than blood to monitor glucose levels has the potential to offer a painless screening method for routine testing.
“Testing for diabetes using saliva, and not blood, is far less invasive and significantly improves the screening process for many patients. This is especially true for children who may be reluctant to have blood taken,” said Professor Abdul-Badi Abou-Samra, Chairman of Internal Medicine at HMC, Director of the Qatar Metabolic Institute and one of the study investigators. “The development of new sensitive screening tools is very important in the fight against diabetes. It could help identify undiagnosed diabetic and prediabetic patients, resulting in improved management and reduced complications,” explained Professor Abou-Samra.
The collaborative team of researchers from HMC, led by Dr. Ramzi Mohammad, Director of the interim Translational Research Institute (iTRI), and WCM-Q, led by Dr. Karsten Suhre, Professor of Physiology and Biophysics and Director of Bioinformatics Core at WCM-Q, is continuing the project to assess the viablility of non-invasive monitoring and screening of diabetes, and a direct translation of the initial findings into the clinics is yet to be seen.
The recent study published in the Journal of Translational Medicine (J Transl Med. 2016 May 18; 14(1):140) demonstrated that saliva can be used for the new test. However, the study showed that saliva contains another molecule that interferes with the readouts. Therefore, current efforts are focused on optimizing the test by introducing an enzymatic reaction to remove the interference and enable the direct use of patient’s saliva for the test.
This study was supported by HMC’s Medical Research Center. Dr. Ibrahim Janahi, Executive Director of MRC and Professor of Pediatrics at WCM-Q, said: “This was a truly collaborative and productive project. It illustrates how an excellent research outcome can derive from the partnership between HMC and WCM-Q.”
Dr. Karsten Suhre added: “For us at WCM-Q, collaborating closely with HMC gives us the opportunity to translate our research from the laboratory to the clinic where it can be of practical use. Translational research of this type is a key priority for Qatar and we are very happy to be working with our colleagues at HMC who are always keen to develop new techniques to continuously improve the care they provide to their patients”.
Dr. Anna Halama from WCM-Q and Dr. Michal Kulinski from the iTRI, who both conducted the research, are now working on the next important project - implementation of the first targeted metabolomics platform in Qatar. Initial validation steps were already accomplished. This tool is allowing for quantification of over 160 small molecules (metabolites) by using Biocrates p150 Kit without sending samples abroad and will be of great benefit for scientists and clinicians working with metabolic diseases.
Hamad Medical Corporation
Hamad Medical Corporation (HMC) is the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East.
For more than four decades, HMC has been dedicated to delivering the safest, most effective and compassionate care to all its patients.
Buy credits to publish your articles on Al Bawaba Biz here